Back to top
more

Akebia Therapeutics (AKBA)

(Real Time Quote from BATS)

$3.74 USD

3.74
1,477,033

+0.02 (0.54%)

Updated Aug 4, 2025 02:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Concert Pharmaceuticals (CNCE) Soars: Stock Adds 5.7% in Session

by Zacks Equity Research

Concert Pharmaceuticals (CNCE) saw its shares rise nearly 6% on the day.

    Zacks Equity Research

    GlycoMimetics (GLYC) Jumps: Stock Rises 11.9%

    by Zacks Equity Research

    GlycoMimetics (GLYC) was a big mover last session, as the company saw its shares nearly 10%on the day amid huge volumes.

      Zacks Equity Research

      BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA

      by Zacks Equity Research

      The FDA currently shows no intent to hold an AdCom to discuss the BLA for BioMarin's (BMRN) pipeline candidate, pegvaliase.

        Zacks Equity Research

        GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down

        by Zacks Equity Research

        GTx (GTXI) posts positive data from a phase II study of enobosarm for treating women with stress urinary incontinence. However, shares dip possibly with the release falling below market estimates.

          Zacks Equity Research

          Ultragenyx's Burosumab Positive in Phase II for XLH and TIO

          by Zacks Equity Research

          Ultragenyx's (RARE) burosumab passes the test with positive data from two phase II studies. The candidate gets evaluated for X-linked hypophosphatemia and tumor-induced osteomalacia.

            Zacks Equity Research

            BioMarin Presents Interim Data on BMN 250 from Phase I/II

            by Zacks Equity Research

            BioMarin's (BMRN) interim data from a current dose escalation phase I/II study on BMN 250 shows improvement signs in cognitive Development Quotient.

              Zacks Equity Research

              Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge

              by Zacks Equity Research

              Akebia Therapeutics (AKBA), could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.

                Zacks Equity Research

                FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down

                by Zacks Equity Research

                Acorda (ACOR) receives a refusal to file (RTF) letter from the FDA in connection with Inbrija's NDA.

                  Zacks Equity Research

                  Strength Seen in Catalent (CTLT): Stock Soars 13.9%

                  by Zacks Equity Research

                  Catalent (CTLT) was a big mover last session, as the company saw its shares rise almost 14% on the day amid huge volumes.

                    Zacks Equity Research

                    Akebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8%

                    by Zacks Equity Research

                    Akebia Therapeutics, Inc. (AKBA) shares rose almost 6% in the last trading session.

                      Zacks Equity Research

                      KalVista Pharmaceuticals (KALV) in Focus: Stock Jumps 6%

                      by Zacks Equity Research

                      KalVista Pharmaceuticals, Inc. (KALV) saw its shares rise 6% in the last trading session.

                        Zacks Equity Research

                        Advanced Accelerator (AAAP) Catches Eye: Stock Jumps 5.4%

                        by Zacks Equity Research

                        Advanced Accelerator Applications S.A. (AAAP) moved big last session, as its shares rose over 5% on the day.

                          Zacks Equity Research

                          Concordia International (CXRX) Looks Good: Stock Jumps 11.4%

                          by Zacks Equity Research

                          Concordia International Corp. (CXRX) shares rose over 11% in the last trading session.

                            Zacks Equity Research

                            Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge

                            by Zacks Equity Research

                            Akebia Therapeutics (AKBA) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision.

                              Zacks Equity Research

                              Moving Average Crossover Alert: Akebia (AKBA)

                              by Zacks Equity Research

                              Akebia Therapeutics, Inc. (AKBA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

                                Zacks Equity Research

                                Cempra (CEMP) Worth a Look: Stock Jumps 7.7% in Session

                                by Zacks Equity Research

                                Cempra, Inc. (CEMP) was a big mover last session, as the company saw its shares rise nearly 8% on the day.

                                  Zacks Equity Research

                                  Earnings Estimates Moving Higher for Akebia Therapeutics (AKBA): Time to Buy?

                                  by Zacks Equity Research

                                  Akebia Therapeutics (AKBA) could be a solid choice for investors as it has seen estimates moving sharply higher over the past four weeks.

                                    Zacks Equity Research

                                    Zoetis (ZTS) Thrives on Product Portfolio, Risks Persist

                                    by Zacks Equity Research

                                    On Dec 29, 2016, we issued an updated research report on Zoetis Inc. (ZTS).

                                      Zacks Equity Research

                                      Akebia Therapeutics (AKBA) Shares March Higher, Can It Continue?

                                      by Zacks Equity Research

                                      As of late, it has definitely been a great time to be an investor in Akebia Therapeutics Inc (AKBA).

                                        Tirthankar Chakraborty headshot

                                        New Strong Buy Stocks for December 28th

                                        by Tirthankar Chakraborty

                                        Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

                                          Zacks Equity Research

                                          Top Ranked Momentum Stocks to Buy for December 28th

                                          by Zacks Equity Research

                                          Here are four stocks with Zacks Rank #1 (Strong Buy) and strong momentum characteristics for investors to consider today, December 28th: